deltatrials

Rheumatoid arthritis Trials in Maidstone, United Kingdom

Conditions / Rheumatoid arthritis / Maidstone, United Kingdom

Clinical trials for Rheumatoid arthritis investigate a range of treatment strategies and patient populations.

16 total trials for this combination

Showing top 10 of 16 trials

Trials

NCT ID Title Status Phase
NCT00750880 An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy. COMPLETED PHASE3
NCT02760407 Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease COMPLETED PHASE3
NCT00883753 An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy COMPLETED PHASE3
NCT01007435 A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis COMPLETED PHASE3
NCT01197755 Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist COMPLETED PHASE3
NCT01197534 Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding. COMPLETED PHASE3
NCT01242514 Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA) TERMINATED PHASE3
NCT01636817 A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics TERMINATED PHASE2
NCT00124982 Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy COMPLETED PHASE3
NCT03120949 Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis COMPLETED PHASE3

Related Pages